Welcome to our dedicated page for Repare Therapeutics news (Ticker: RPTX), a resource for investors and traders seeking the latest updates and insights on Repare Therapeutics stock.
Repare Therapeutics Inc (RPTX) is a clinical-stage biotechnology company pioneering precision oncology therapies through its synthetic lethality platform and CRISPR-enabled target discovery. This page aggregates official announcements, research breakthroughs, and strategic developments critical for understanding the company's progress in developing targeted cancer treatments.
Investors and researchers will find comprehensive updates on clinical trial milestones, regulatory filings, and scientific collaborations. The curated news collection includes updates on therapeutic candidates, partnership agreements, and peer-reviewed research findings, providing a centralized hub for tracking RPTX's contributions to oncology innovation.
Key content areas cover clinical-stage developments, research publications, and strategic partnerships that demonstrate the company's scientific rigor. All materials are sourced from verified corporate communications and reputable industry publications to ensure reliability.
Bookmark this page for streamlined access to Repare Therapeutics' latest advancements in CRISPR-based drug discovery and precision oncology solutions. Check back regularly for real-time insights into their mission to develop therapies targeting genetic vulnerabilities in cancer cells.
Repare Therapeutics (NASDAQ: RPTX) announced key leadership changes effective April 11, 2025. Steve Forte, current Executive Vice President and CFO, has been appointed as President, CEO, and Board Director, while maintaining his CFO role. Lloyd M. Segal has resigned from his positions as President, CEO, and Board Director to pursue other opportunities.
Forte, who joined Repare in 2019, brings over 20 years of finance and biotech leadership experience. He previously served as CFO at Clementia Pharmaceuticals, which was acquired by Ipsen for $1.3 billion. Additionally, Sandra Alves has been promoted from VP and Corporate Controller to Chief Accounting Officer.
The clinical-stage precision oncology company is currently advancing three Phase 1 trials: the MYTHIC trial (lunresertib with Debio 0123) expecting completion in Q2 2025, the POLAR trial (RP-3467) with data expected in Q3 2025, and the LIONS trial (RP-1664 with olaparib) with initial data expected in Q4 2025. The company is also exploring strategic alternatives and partnerships for lunresertib and camonsertib.
Repare Therapeutics (Nasdaq: RPTX) has announced the granting of stock options to two new employees through its 2024 Inducement Plan. The Compensation Committee approved two separate grants:
1. A stock option granted on November 5, 2024, with an exercise price of $3.59 per share
2. A stock option granted on March 5, 2025, with an exercise price of $1.17 per share
The total aggregate amounts to 22,200 common shares. Both options have ten-year terms and will vest over four years, with 25% vesting after one year and the remainder vesting in monthly installments. These grants were made as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4).
Repare Therapeutics (RPTX) has announced significant business restructuring and clinical updates for Q4 and full year 2024. The company is implementing a 75% workforce reduction while maintaining $152.8 million in cash reserves, extending runway to late-2027. Three key clinical trials are progressing with expected readouts in 2025:
- POLAR trial (RP-3467 Polθ inhibitor) data expected Q3 2025
- LIONS trial (RP-1664 PLK4 inhibitor) readout expected Q4 2025
- MYTHIC trial evaluating lunresertib combination therapy
Financial highlights include revenue from collaborations of $53.5 million for 2024, reduced R&D expenses of $115.9 million (down from $133.6 million in 2023), and a net loss of $84.7 million ($2.00 per share) for 2024.
Repare Therapeutics (RPTX) announced a strategic portfolio re-prioritization focusing on two Phase 1 clinical programs: RP-1664 (PLK4 inhibitor) and RP-3467 (Polθ ATPase inhibitor). The company will seek partnerships for its Lunre+Camo program before pivotal development.
The restructuring includes cost and headcount reductions, extending cash runway to mid-2027. With approximately $153 million in cash at 2024-end, Repare will concentrate on achieving near-term milestones, with initial clinical readouts expected in Q3 2025.
Key upcoming milestones include: RP-1664's Phase 1/2 expansion trial initiation in pediatric neuroblastoma (Q3 2025) and LIONS trial data (Q4 2025); RP-3467's POLAR trial data in Q3 2025. The company will discontinue development of lunresertib and camonsertib in other studies unless securing partnership agreements.
Repare Therapeutics (RPTX) reported positive results from its MYTHIC Phase 1 gynecologic expansion trial combining lunresertib and camonsertib (Lunre+Camo). The trial showed a 25.9% overall response rate in endometrial cancer and 37.5% in platinum-resistant ovarian cancer. Nearly half of patients maintained progression-free survival at 24 weeks.
The study included heavily pretreated patients, with many receiving the treatment as fourth line or beyond. In endometrial cancer patients, 100% had prior platinum therapy and 77.8% received immune checkpoint inhibitors. For ovarian cancer patients, all were platinum-resistant or ineligible, with 45.8% having received prior PARP inhibitors.
The company plans to initiate a registrational Phase 3 trial for endometrial cancer in second half of 2025.
Repare Therapeutics (Nasdaq: RPTX) announced a webcast presentation of data from its Phase 1 MYTHIC clinical trial on December 12, 2024. The trial evaluates the combination of lunresertib and camonsertib at the recommended Phase 2 dose in patients with platinum-resistant ovarian and endometrial cancers with specific genetic markers (CCNE1 amplification or FBXW7 or PPP2R1A mutations).
The presentation will feature Dr. Brian Slomovitz, Director of Gynecologic Oncology at Mount Sinai Medical Center, alongside Repare's executive management team. The event will be accessible via conference call and live video webcast through the company's investor relations website.
Repare Therapeutics has announced a Cooperative Research and Development Agreement (CRADA) with the US National Cancer Institute's Cancer Therapy Evaluation Program (CTEP) to advance camonsertib, their oral ATR inhibitor for cancer treatment. The drug has shown significant anti-tumor activity in preclinical and clinical studies, particularly demonstrating prolonged progression-free survival in ATM-mutated non-small cell lung cancer patients. Recent Phase 1 results combining camonsertib with radiotherapy showed complete responses in patients with ATM-altered tumors. CTEP will focus on combination studies involving camonsertib with radiation therapy and translational studies for biomarker identification.
Repare Therapeutics (RPTX) reported Q3 2024 financial results and clinical updates. The company ended Q3 with $179.4 million in cash and equivalents, expected to fund operations into H2 2026. Q3 net loss widened to $34.4 million ($0.81/share) from $18.9 million in Q3 2023. The company reduced workforce by 25% in August 2024 to focus on clinical-stage programs.
Key pipeline updates include upcoming MYTHIC trial data in December 2024, positive safety data presentation at EORTC-NCI-AACR, and first patient dosed in POLAR trial. The company plans to begin a registrational trial in 2025 for its lunresertib-camonsertib combination therapy in gynecologic cancers.
Repare Therapeutics (RPTX) presented updated data from its Phase 1 MYTHIC clinical trial, demonstrating successful management of anemia through an individualized dosing schedule of lunresertib (PKMYT1 inhibitor) and camonsertib (ATR inhibitor) combination therapy. The new schedule significantly reduced Grade 3 anemia rates to 22.6% from 51.4%, while maintaining clinical benefits. Key improvements include reduced red blood cell transfusions (13% vs 43%), fewer dose interruptions (13% vs 23%), and lower dose reductions (6% vs 17%). The trial showed no thrombocytopenia and no serious neutropenia, with maintained antitumor activity and radiographic regressions.
Repare Therapeutics (Nasdaq: RPTX) has dosed the first patient in its Phase 1 POLAR clinical trial for RP-3467, a Polθ ATPase inhibitor. The trial will evaluate RP-3467 alone and in combination with the PARP inhibitor olaparib. RP-3467 is Repare's fourth clinical program and has shown promising preclinical results, including complete and durable tumor regressions when combined with olaparib, without additional toxicities.
The POLAR trial (NCT06560632) aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of RP-3467. It will enroll approximately 52 patients with advanced solid tumors, including ovarian, breast, prostate, and pancreatic cancers. The study's primary objectives are to evaluate safety and tolerability, and determine a recommended Phase 2 dose for the combination therapy.
